A study, conducted by KNCV Tuberculosis Foundation and TB Alliance, shows that the adoption of BPal will be accepted and feasible in the three high drug-resistant tuberculosis (DR-TB) burden countries; Indonesia, Kyrgyzstan and Nigeria. BPal is a 6 month oral regimen composed of bedaquiline, pretomanid and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) and is a potential alternative for at least 20 months of individualized treatment regimens (ITR) – which has low tolerability, treatment adherence and success rates.
According to the study, published in the peer reviewed BMC Journal, BPaL could increase the treatment success rate and alleviate the individual and health care system burden of DR-TB. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints.
The publication ‘Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients’ can be found here.
Click here to view other KNCV publications.